Researchers at Cedars-Sinai Medical Center have developed a vaccine that helps the immune system attack these tumors called glioblastoma multiforme (GBM).
In a Phase I clinical trial, which tests drug safety, participants lived a median (middle number) of 38.4 months. Typical lifespan with these tumors is 14.6 months after standard therapy which includes radiation and chemotherapy.
The time before the tumor returned was also longer - 16.9 months compared to 6.9 months.
Some 49 to 66 months following treatment, six patients were free of the disease, and the tumor had not returned. Another eight patients were still alive.